Skip to content
sellWeak

Third Rock Ventures IV, L.P. sold $5.1M of TNGX

owner at Tango Therapeutics, Inc.. 729,365 shares at an average of $7.00, traded Sep 5, 2025, filed Sep 9, 2025.

Warning score
37
Value
$5.1M
729,365 shares
Holdings after
14,727,516
-5% from before
From 52-week low
+531%
low $1.10, close $6.94
From 52-week high
-34%
high $10.50, as of Sep 5, 2025

Score components

  • Role
    10% owner
    +12
  • Trade size
    $5.1M at market
    +25
  • Share of holdings sold
    Sold 4.7% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

TNGXOct 9, 2026 · close 23.81
Since filing Sep 9, 2025: +249.1%SPY +21.3% · excess +227.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-25-199177, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 5, 2025SOpen-market sale
Common Stock
-642,906$7.00$4.5M14,813,975Sep 9, 2025
Sep 8, 2025SOpen-market sale
Common Stock
-86,459$7.04$609k14,727,516Sep 9, 2025

Related signals

Other insiders at Tango Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
18Weak
TNGXsell 210b5-1
Tango Therapeutics, Inc.
Adam Crystal
President, R&D
$661k
27,000 shares
-19%
20Weak
TNGXsell 210b5-1
Tango Therapeutics, Inc.
Jessica Newcomb
Principal Accounting Officer
$199k
8,200 shares
-12%
9Weak
TNGXsell10b5-1
Tango Therapeutics, Inc.
Adam Crystal
President, R&D
$604k
27,000 shares
-19%
37Weak
TNGXsell
Tango Therapeutics, Inc.
Third Rock Ventures IV, L.P.
owner
$4.0M
500,000 shares
-3%
37Weak
TNGXsell
Tango Therapeutics, Inc.
Third Rock Ventures IV, L.P.
owner
$2.6M
363,541 shares
-2%
37Weak
TNGXsell
Tango Therapeutics, Inc.
Third Rock Ventures IV, L.P.
owner
$2.1M
302,194 shares
-2%
37Weak
TNGXsell
Tango Therapeutics, Inc.
Third Rock Ventures IV, L.P.
owner
$7.7M
1,100,000 shares
-7%
30Weak
TNGXsell 3
Tango Therapeutics, Inc.
Douglas Barry
General Counsel
$16k
5,330 shares
-7%
42Moderate
TNGXsell 3
Tango Therapeutics, Inc.
Daniella Beckman
Chief Financial Officer
$25k
8,232 shares
-5%
36Weak
TNGXsell 3
Tango Therapeutics, Inc.
Adam Crystal
See Remarks
$44k
14,283 shares
-8%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Third Rock Ventures IV, L.P. sold $5.1M of TNGX | InsiderTell